Since its approval in April 2018, osimertinib has been widely adopted as first-line therapy for
patients with advanced EGFR-mutant non -small cell lung cancer (NSCLC). Understanding …

Importance Non-Hispanic Black individuals experience a higher burden of COVID-19 than
the general population; hence, there is an urgent need to characterize the unique clinical …

Importance Cytokine storm due to COVID-19 can cause high morbidity and mortality and may
be more common in patients with cancer treated with immunotherapy (IO) due to immune …

Importance Androgen deprivation therapy (ADT) has been theorized to decrease the severity
of SARS-CoV-2 infection in patients with prostate cancer owing to a potential decrease in …

ROS1-rearranged (also known as ROS1 fusion-positive) non-small-cell lung cancer is an
uncommon but distinct molecular subgroup seen in approximately 1–2% of cases. Oncogene …

Introduction Patients with EGFR-mutant lung cancer who have had disease progression on
osimertinib commonly receive platinum doublet chemotherapy, but whether adding …

DISCUSSION The first reported case of heart failure with reduced LVEF with osimertinib
developed within 3 weeks of starting therapy (5), whereas our patient presented with symptoms …

Objectives Neoadjuvant therapy prior to surgical resection for locally advanced lung cancer
has evolved to incorporate systemic cytotoxic chemotherapy +/- immunotherapy +/- …

Importance Systematic data on the association between anticancer therapies and
thromboembolic events (TEEs) in patients with COVID-19 are lacking. Objective To assess the …

MET gene amplification is an established mechanism of acquired resistance to all classes
of EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated lung cancer. Novel strategies to …